It relaxes vascular smooth muscle, releases nitric oxide (NO) through metabolism to generate isosorbide mononitrate, activates guanylate cyclase to increase cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, reducing myocardial oxygen consumption and increasing oxygen supply, and relieving angina pectoris.

This product is a non-steroidal antipyretic analgesic with antipyretic, analgesic and anti-inflammatory effects. It has almost no effect on platelet aggregation.

Regulate the excitability of the central nervous system, balance the excitation and inhibition of the brain, and improve the regulatory function of the brain

Regulate the excitability of the central nervous system, balance the excitation and inhibition of the brain, and improve the regulatory function of the brain

May be involved in improving brain metabolism and enhancing memory

Improve brain metabolism and enhance memory

This product is an aminoglycoside antibiotic. It has good antibacterial effects on various Gram-negative and Gram-positive bacteria, and has good effects on various Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococci), but most methicillin-resistant strains are resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with β-lactams, most of them can obtain a synergistic antibacterial effect. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. In recent years, the number of Gram-negative bacteria resistant to gentamicin has increased significantly.